Related references
Note: Only part of the references are listed.AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial
Andrey A. Ivashchenko et al.
CLINICAL INFECTIOUS DISEASES (2021)
Outcome of noncritical COVID-19 patients with early hospitalization and early antiviral treatment outside the ICU
Nursel Calik Basaran et al.
TURKISH JOURNAL OF MEDICAL SCIENCES (2021)
Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID-19
Kei Irie et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2020)
A Review of Coronavirus Disease-2019 (COVID-19)
Tanu Singhal
INDIAN JOURNAL OF PEDIATRICS (2020)
Non-steroidal anti-inflammatory drugs in management of COVID-19; A systematic review on current evidence
Mahmoud Yousefifard et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2020)
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19) A Review
James M. Sanders et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Favipiravir, an antiviral for COVID-19?
Eric A. Coomes et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
Qingxian Cai et al.
ENGINEERING (2020)
Effect of favipiravir and an anti-inflammatory strategy for COVID-19
Hitoshi Yamamura et al.
CRITICAL CARE (2020)
Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series
Kent Doi et al.
CRITICAL CARE (2020)
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
Alessandro Liberati et al.
ANNALS OF INTERNAL MEDICINE (2009)
Share Paper
